Molecular Partners AG (XSWX:MOLN) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MOLN Molecular Partners AG XSWX:MOLN
29 GF Score
Price CHF3.18
GF Value CHF0.37
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG FFO per Share?

FFO per Share only applies to REITs.

XSWX:MOLN
29GF Score
Molecular Partners AG XSWX:MOLN
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Molecular Partners AG (XSWX:MOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of CHF3.18 is trading 759.5% above its estimated GF Value™ of CHF0.37. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for XSWX:MOLN:

  • FFO per Share:
  • GF Value™: CHF0.37 vs. price of CHF3.18 (759.5% above fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the XSWX:MOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
29GF Score

Get the complete analysis for XSWX:MOLN

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.18
Price
CHF0.37
GF Value